Haemonetics (HAE) Net Cash Flow (2009 - 2026)

Haemonetics' Net Cash Flow history runs 18 years deep, the most recent figure standing at -$117.2 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 595.25% year-over-year to -$117.2 million in Q1 2026; TTM through Mar 2026 was -$64.8 million, a 150.36% decrease from a year earlier, with the FY2026 full-year figure at -$64.8 million, down 150.36% from the prior year.
• Net Cash Flow declined to -$117.2 million in Q1 2026 per HAE's latest filing, from $66.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $167.1 million in Q2 2024 and bottomed at -$160.0 million in Q4 2023.
• The 5-year median for Net Cash Flow is $3.8 million (2023), against an average of $3.3 million.
• Across the five-year window, Net Cash Flow sank 635.35% in 2023 and jumped 5077.38% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at -$21.8 million in 2022, then sank by 635.35% to -$160.0 million in 2023, then soared by 117.35% to $27.8 million in 2024, then surged by 138.1% to $66.1 million in 2025, then sank by 277.18% to -$117.2 million in 2026.
• Per Business Quant, the three latest HAE Net Cash Flow figures stand at -$117.2 million (Q1 2026), $66.1 million (Q4 2025), and $4.3 million (Q3 2025).